Discussing Increased Prevalence of NAFLD and NASH, and the Current Lack of Treatments

Despite how common nonalcoholic fatty liver disease is, there are currently no approved medications on the market. Instead, patients have to rely on lifestyle modification, such as weight loss, increased physical activity, and dietary changes. However, that may change.

One of the most common causes of liver disease in the United States is nonalcoholic fatty liver disease (NAFLD), affecting between 30% and 40% of adults, according to the National Institute of Diabetes, and Digestive and Kidney Diseases. It’s a condition in which excess fat is stored in the liver—a buildup that is not caused by heavy alcohol use.

Despite how common NAFLD is, there are currently no approved medications on the market. In this podcast, we talk to a clinician involved with a program that uses lifestyle management and a patient advocate, who is trying to shape policy to help patients with NAFLD and its more extreme version, nonalcoholic steatohepatitis (NASH).

To listen, login to the website.

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg

Listen above or through one of these podcast services:

Read more about NAFLD and NASH:

Studies Point to Empagliflozin as First Choice for Fatty Liver Disease in T2D

Drug Approvals That Dr Aimee Tharaldson Is Keeping an Eye on for 2019

Analyzing the Near-Term Pipeline for Specialty Drugs

Dr Aimee Tharaldson: We're Keeping an Eye on Future NASH Treatments

Related Videos
Eneline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA
Nancy Reau, MD
Nancy Reau, MD
Nancy Reau, MD
Nancy Reau, MD
Related Content
CH LogoCenter for Biosimilars Logo